Fibrocell Science, Inc. (FCSC) saw its loss widen to $5.01 million, or $0.60 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $1.41 million, or $0.23 a share.

The company has not recorded any revenues for the current quarter. However, it has reported a revenue of $0.02 million for the previous year period.

Operating loss for the quarter was $4.45 million, compared with an operating loss of $6.67 million in the previous year period.

"This is an exciting time at Fibrocell as our gene therapy candidates continue to make significant progress that moves us closer to our goal of transforming the lives of patients suffering with rare and debilitating genetic diseases of the skin and connective tissue," said John Maslowski, chief executive officer of Fibrocell. "We look forward to safety and efficacy data in the third quarter of 2017 from the first cohort of patients in the Phase 1/2 study of FCX-007, our product candidate for the treatment of recessive dystrophic epidermolysis bullosa." "In addition, we continue to make progress in the pre-clinical development of our gene therapy candidate for the treatment of linear scleroderma, FCX-013, and expect to submit an Investigational New Drug Application to the FDA in the fourth quarter of 2017," added Mr. Maslowski.